Core Viewpoint - Longshen Rongfa (300534.SZ) announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., received a new drug production license from the Gansu Provincial Drug Administration, effective September 25, 2025, due to the application for the reduction of commissioned production of a specific medicine [1] Group 1 - The change in the drug production license is primarily due to the application for the reduction of the commissioned production of Xuanfei Zhiso Decoction (National Drug Approval Number Z20050288) [1] - The completion of the license change procedures is in accordance with legal requirements and will not have a significant impact on the company's production and operations [1] - Investors are advised to make cautious decisions and pay attention to investment risks [1]
陇神戎发(300534.SZ)：控股子公司取得换发后的《药品生产许可证》